(AZN) Community Analysis from
Bulls REASONS TO BUY
|
75%
agree
29 votes
|
MedImmune acquistion will provide long term pipeline |
|
50%
agree
2 votes
|
AstraZeneca has a highly profitable portfolio of young medicines |
Bears REASONS TO SELL
|
42%
agree
14 votes
|
AstraZeneca experienced several setbacks in phase III drugs in 2006 |
|
20%
agree
5 votes
|
Is AstraZeneca's Pipeline Running Dry? |
|
28%
agree
7 votes
|
MedImmune acquistion - too high a price paid? |
June 19, 2013
(Stock Blog Hub,
5/9/13)
AstraZeneca (AZN) recently announced that it has entered into an agreement with UK-based company, Oxford Cancer Biomarkers Ltd. As per the terms of the agreement, Oxford Cancer...(read more)
(Stock Blog Hub,
4/1/13)
AstraZeneca (AZN) recently announced that it plans to initiate strategic reforms in its research and development (R&D) segment. As per proposed plans, the...(read more)
(Wealth Daily,
4/24/13)
Pharmaceutical company AstraZeneca (NYSE:AZN) is betting big on a small biotech company's technology...
AstraZeneca (AZN) Company Overview
AstraZeneca is one of the world's largest pharmaceutical companies, with FY2009 sales of $32.8 billion and $7.5 billion in profits.[1] AstraZeneca's wide-ranging portfolio of products includes some of the world's most successful drugs. Among other blockbusters, AstraZeneca produces cholesterol fighter Crestor and the ubiquitous "purple pill" Nexium, one of the best-selling drugs in history.
(Read more at Wikinvest
) What's in this AZN analysis on Wikinvest...
- Corporate Overview
- Blockbusters and Major Therapeutic Areas
- Business Growth
- Research and Development
- The Pipeline
- MedImmune Acquisition
- Trends & Forces
- Tightening FDA Regulations
- H1N1 Vaccines
- Emerging Markets
- Generic Drugs & Patent Protection
- Unfavorable Legislative Environments
- Outsourcing
- Comparison to Competitors
- References
